<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2    DOSAGE AND ADMINISTRATION <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Premedicate with an H1 antagonist. (2.3)<BR>                           <BR>                           Administer 400 mg/m2 initial dose as a 120-minute intravenous infusion followed by 250 mg/m2 weekly infused over 60 minutes. (2.1, 2.2)<BR>                           <BR>                           Initiate Erbitux one week prior to initiation of radiation therapy. Complete Erbitux administration 1 hour prior to platinum-based therapy with 5-FU (2.1) and FOLFIRI (2.2).<BR>                           <BR>                           Reduce the infusion rate by 50% for NCI CTC Grade 1 or 2 infusion reactions and non-serious NCI CTC Grade 3 infusion reaction. (2.4)<BR>                           <BR>                           Permanently discontinue for serious infusion reactions. (2.4)<BR>                           <BR>                           Withhold infusion for severe, persistent acneiform rash. Reduce dose for recurrent, severe rash. (2.4)<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1   Squamous Cell Carcinoma of the Head and Neck<BR>                     <BR>                        Erbitux in combination with radiation therapy or in combination with platinum-based therapy with 5-FU:<BR>                        <BR>                           The recommended initial dose is 400 mg/m2 administered one week prior to initiation of a course of radiation therapy or on the day of initiation of platinum-based therapy with 5-FU as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min). Complete Erbitux administration 1 hour prior to platinum-based therapy with 5-FU.<BR>                           The recommended subsequent weekly dose (all other infusions) is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) for the duration of radiation therapy (6–7 weeks) or until disease progression or unacceptable toxicity when administered in combination with platinum-based therapy with 5-FU. Complete Erbitux administration 1 hour prior to radiation therapy or platinum-based therapy with 5-FU.<BR>                           <BR>                        <BR>                        Erbitux monotherapy:<BR>                        <BR>                           The recommended initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min).<BR>                           The recommended subsequent weekly dose (all other infusions) is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2   Colorectal Cancer<BR>                     <BR>                        <BR>                           <BR>                              Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment. Only patients whose tumors are K-Ras mutation-negative (wild-type) should receive Erbitux.<BR>                           <BR>                           <BR>                              The recommended initial dose, either as monotherapy or in combination with irinotecan or FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min). Complete Erbitux administration 1 hour prior to FOLFIRI.<BR>                           <BR>                           <BR>                              The recommended subsequent weekly dose, either as monotherapy or in combination with irinotecan or FOLFIRI, is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Complete Erbitux administration 1 hour prior to FOLFIRI.<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.3   Recommended Premedication<BR>                     <BR>                        Premedicate with an H1 antagonist (eg, 50 mg of diphenhydramine) intravenously 30–60 minutes prior to the first dose; premedication should be administered for subsequent Erbitux doses based upon clinical judgment and presence/severity of prior infusion reactions.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.4   Dose Modifications<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Infusion Reactions<BR>                           <BR>                              Reduce the infusion rate by 50% for NCI CTC Grade 1 or 2 and non-serious NCI CTC Grade 3 infusion reaction.<BR>                              Immediately and permanently discontinue Erbitux for serious infusion reactions, requiring medical intervention and/or hospitalization. [See Warnings and Precautions (5.1)<BR>                                 .]<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Dermatologic Toxicity<BR>                           <BR>                              Recommended dose modifications for severe (NCI CTC Grade 3 or 4) acneiform rash are specified in  Table 1. [See Warnings and Precautions (5.4)<BR>                                 .]<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="table1" width="100%"><BR>                                 <caption>Table  1: Erbitux Dose Modification Guidelines for Rash</caption><BR>                                 <colgroup><BR>                                    <col width="20%"/><BR>                                    <col width="28%"/><BR>                                    <col width="24%"/><BR>                                    <col width="28%"/><BR>                                 </colgroup><BR>                                 <thead><BR>                                    <tr><BR>                                       <th align="center" colspan="1" rowspan="1" styleCode="Toprule Botrule" valign="bottom"><BR>                                          <content styleCode="bold">Severe Acneiform <br/>Rash</content><BR>                                       </th><BR>                                       <th align="center" colspan="1" rowspan="1" styleCode="Toprule Botrule" valign="bottom"><BR>                                          <content styleCode="bold">Erbitux</content><BR>                                       </th><BR>                                       <th align="center" colspan="1" rowspan="1" styleCode="Toprule Botrule" valign="bottom"><BR>                                          <content styleCode="bold">Outcome</content><BR>                                       </th><BR>                                       <th align="center" colspan="1" rowspan="1" styleCode="Toprule Botrule" valign="bottom"><BR>                                          <content styleCode="bold">Erbitux Dose <br/>Modification</content><BR>                                       </th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr valign="top"><BR>                                       <td align="left" colspan="1" rowspan="1">1st occurrence</td><BR>                                       <td align="center" colspan="1" rowspan="1">Delay infusion 1 to 2 weeks</td><BR>                                       <td align="center" colspan="1" rowspan="1">Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1">Continue at 250 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="left" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="left" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">No Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">Discontinue Erbitux</td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="left" colspan="1" rowspan="1">2nd occurrence</td><BR>                                       <td align="center" colspan="1" rowspan="1">Delay infusion 1 to 2 weeks </td><BR>                                       <td align="center" colspan="1" rowspan="1">Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1">Reduce dose to 200 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">No Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">Discontinue Erbitux</td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="left" colspan="1" rowspan="1">3rd occurrence</td><BR>                                       <td align="center" colspan="1" rowspan="1">Delay infusion 1 to 2 weeks</td><BR>                                       <td align="center" colspan="1" rowspan="1">Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1">Reduce dose to 150 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">No Improvement</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">Discontinue Erbitux</td><BR>                                    </tr><BR>                                    <tr valign="top"><BR>                                       <td align="left" colspan="1" rowspan="1" styleCode="Botrule">4th occurrence</td><BR>                                       <td align="center" colspan="1" rowspan="1" styleCode="Botrule">Discontinue Erbitux</td><BR>                                       <td align="left" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                       <td align="left" colspan="1" rowspan="1" styleCode="Botrule">&#160;</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.5   Preparation for Administration<BR>                     <BR>                        <BR>                           Do not administer Erbitux as an intravenous push or bolus.<BR>                        <BR>                        Administer via infusion pump or syringe pump. Do not exceed an infusion rate of 10 mg/min.<BR>                        <BR>                           Administer through a low protein binding 0.22-micrometer in-line filter.<BR>                        <BR>                        Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.<BR>                        The solution should be clear and colorless and may contain a small amount of easily visible, white, amorphous, cetuximab particulates. Do not shake or dilute.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>